Broadly Protective Antibodies Could Lead to Better Flu Treatments and Vaccines | NIH: National Institute of Allergy and Infectious Diseases

Broadly Protective Antibodies Could Lead to Better Flu Treatments and Vaccines | NIH: National Institute of Allergy and Infectious Diseases

Friday, October 25, 2019 Broadly Protective Antibodies Could Lead to Better Flu Treatments and Vaccines Most flu vaccines work by teaching the immune system to attack hemagglutinin (HA) proteins on the surface of the flu virus. However, neuraminidase (NA) surface proteins could also be a good target for flu vaccines and treatments. NIAID-supported researchers have discovered three new antibodies which bind to influenza NA proteins. These antibodies appear to provide broad, robust protection against many different kinds of influenza when tested in mice, and they could provide the basis for better treatments or vaccines for influenza in people.